AQXP vs. AMPH, GERN, IRON, WVE, BLTE, MNKD, DVAX, ARQT, GLPG, and INDV
Should you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Geron (GERN), Disc Medicine (IRON), Wave Life Sciences (WVE), Belite Bio (BLTE), MannKind (MNKD), Dynavax Technologies (DVAX), Arcutis Biotherapeutics (ARQT), Galapagos (GLPG), and Indivior (INDV). These companies are all part of the "medical" sector.
Aquinox Pharmaceuticals vs.
Aquinox Pharmaceuticals (NASDAQ:AQXP) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk.
Amphastar Pharmaceuticals has higher revenue and earnings than Aquinox Pharmaceuticals.
Amphastar Pharmaceuticals received 93 more outperform votes than Aquinox Pharmaceuticals when rated by MarketBeat users. However, 71.88% of users gave Aquinox Pharmaceuticals an outperform vote while only 66.22% of users gave Amphastar Pharmaceuticals an outperform vote.
Aquinox Pharmaceuticals has a beta of -7.37, meaning that its stock price is 837% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.
Amphastar Pharmaceuticals has a consensus price target of $60.33, indicating a potential upside of 67.45%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Amphastar Pharmaceuticals is more favorable than Aquinox Pharmaceuticals.
Amphastar Pharmaceuticals has a net margin of 21.80% compared to Aquinox Pharmaceuticals' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Aquinox Pharmaceuticals' return on equity.
In the previous week, Amphastar Pharmaceuticals had 4 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 4 mentions for Amphastar Pharmaceuticals and 0 mentions for Aquinox Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.12 beat Aquinox Pharmaceuticals' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.
71.7% of Aquinox Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are owned by company insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Amphastar Pharmaceuticals beats Aquinox Pharmaceuticals on 13 of the 16 factors compared between the two stocks.
Get Aquinox Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquinox Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AQXP) was last updated on 1/22/2025 by MarketBeat.com Staff
